Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab in Hospitalized COVID-19 Pneumonia
NCT04460105Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of lanadelumab in COVID-19 pneumonia (4 arms), sponsored by Takeda. Primary endpoint: Treatment emergent adverse events at Day 29. Planned start Oct 2020; status: withdrawn.
02
Drugs
lanadelumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04460105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460105.